Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center

J BUON. 2021 Sep-Oct;26(5):2026-2032.

Abstract

Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).

Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).

Results: More than half of the patients could go on with venetoclax for only a few months.

Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Azacitidine / therapeutic use*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
  • Decitabine / therapeutic use*
  • Drug Combinations
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Methyltransferases / antagonists & inhibitors*
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Sulfonamides / therapeutic use*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Drug Combinations
  • Sulfonamides
  • Decitabine
  • Methyltransferases
  • Azacitidine
  • venetoclax